n.a. (ACT)

Jim Cramer says the antitrust environment out there will make it difficult for any railroad mergers to be approved by regulators.

Investors are gearing up for another assessment of the global economy, as the Fed Prepares to release the minutes of its March meeting.

The latest rules are seen likely to prompt a rethink of the $150 billion pharmaceuticals deal.

Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.

TheStreet's Jim Cramer said Valeant Pharmaceuticals' (VRX) move to appoint billionaire investor Bill Ackman to the board of directors isn't enough and a government monitor is needed.

Despite the financial hardships plaguing some economies, healthcare M&A is still on the rise and experts indicate there is no sign of it slowing.

Laval, Quebec-based Valeant Pharmaceuticals International Inc. (VRX) announced on Thursday that it would purchase privately owned Sprout Pharmaceuticals Inc. for $1 billion.

TheStreet highlights 3 stocks pushing the drugs industry higher today.

We put our large cash position to work this week, building our stakes in two portfolio names.

The Botox maker now has complete 'facial domination,' Cramer says.

Glenview Capital's Larry Robbins has hit the nail on the head with his health care picks in recent years, but they're not his only investments you should be watching.

But investors are likely to be wary ahead of the Fed meeting.

This week, we added to two portfolio holdings, took some profits off the table in others, and exited one position.

Cramer is impressed by Rite Aid, even though it is expensive, and Receptos, which he says is the best early-stage biotech.

Cramer will be watching earnings from Sears, Lululemon and Cisco, among others, next week.

We made few moves in the portfolio this week as mixed data produced volatile trading across asset classes.

We have tremendous confidence in Actavis' ability to deliver.

This week, we swapped new positions for old in the energy and health care sectors, as the market ended in the red.

Actavis' attractive near to medium-term organic growth profile is not reflected in current valuation levels.

TheStreet highlights 3 stocks pushing the drugs industry higher today.

The new drug complements the company's offer in the field.

We added two new positions to the portfolio this week as the S&P 500 moved slightly higher.

John Paulson said in a 2014 interview that he expected high levels of M&A activity to continue "for the foreseeable future." He has invested accordingly, and it is paying off.

TheStreet’s Jim Cramer answers your Twitter questions from the floor of the New York Stock Exchange.

Hedge funds socked money into health care, industrials and energy last quarter, according to S&P Capital IQ. Here are the top five stock purchases made by large hedge fund managers.

Today shows why they're a problem, as are all transports.

Hedge funds were buying these five stocks in bulk in the most recently reported quarter, but that doesn't necessarily mean you should add them to your portfolio too.

Three years after first making the case for Alibaba, Dan Loeb is done. He has set his sights on other investments, instead.